Glenn Sblendorio To Retire As President And Chief Financial Officer From The Medicines Company (MDCO)

PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) announced today that Glenn Sblendorio, President and Chief Financial Officer, will retire from the company effective March 31, 2016. As of January 1, 2016, Mr. Sblendorio will be relinquishing his seat on the Board of Directors and his operational responsibilities will be assumed by others within the company. William O'Connor, Senior Vice President & Chief Accounting Officer, who has been with The Medicines Company since 2006, will succeed Mr. Sblendorio as Chief Financial Officer.

Suggested Articles

The deal grants Sarepta the exclusive right to use Hansa Biopharma’s imlifidase to eliminate neutralizing antibodies in DMD and LGMD patients.

Annexon has grabbed a healthy $100 million round to take its clinical work closer to the finishing line as it tees up shots on multiple targets.

Researchers have demonstrated that targeting a potassium ion channel called Kv2.1 can protect the brain from neuronal damage after a stroke.